Skip to main content
. 2019 Mar 18;19(5):3505–3518. doi: 10.3892/mmr.2019.10051

Figure 5.

Figure 5.

Effects of TGF-β1 on the motility of human osteoblasts are dependent upon PI3K/AKT signalling. (A) Migration of hFOB1.19 human osteoblasts treated for 24 h with 1 ng/ml TGF-β1 and/or 10 µM LY, a PI3K/AKT inhibitor, as determined by a scratch-wound assay. The number of cells entering the wound indicated the migration of cells. (B) Migration of osteoblasts treated for 24 h with 1 ng/ml TGF-β1 and/or 10 µM LY, as determined by a Transwell assay. Scale bar, 200 µm. Data are presented as the mean ± standard deviation. *P<0.05, **P<0.01 and ***P<0.001 vs. NC. AKT, protein kinase B; LY, LY294002; NC, negative control; PI3K, phosphatidylinositol 3-kinase; TGF-β1, transforming growth factor β1.